We are taking a diligent and broad approach in some of the most challenging, but potentially most impactful, areas of cancer research. We have developed a robust pipeline of homegrown and licensed/partnered clinical assets with a diverse range of mode of actions, including cancer cell-directed and immuno-oncology investigational therapies. It’s the smart combination of these approaches that may offer the greatest benefit for people living with cancer.
We have developed a robust pipeline of clinical assets including immuno-oncology investigational therapies, find out more about them here.
